NO20076120L - Stabile nanopartikkelformuleringer - Google Patents

Stabile nanopartikkelformuleringer

Info

Publication number
NO20076120L
NO20076120L NO20076120A NO20076120A NO20076120L NO 20076120 L NO20076120 L NO 20076120L NO 20076120 A NO20076120 A NO 20076120A NO 20076120 A NO20076120 A NO 20076120A NO 20076120 L NO20076120 L NO 20076120L
Authority
NO
Norway
Prior art keywords
nanoparticle formulations
stable nanoparticle
formulations
stable
preparing
Prior art date
Application number
NO20076120A
Other languages
English (en)
Norwegian (no)
Inventor
Khawla Abdullah Abu-Izza
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of NO20076120L publication Critical patent/NO20076120L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20076120A 2005-05-05 2007-11-27 Stabile nanopartikkelformuleringer NO20076120L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67808605P 2005-05-05 2005-05-05
PCT/US2006/017059 WO2007086911A2 (fr) 2005-05-05 2006-05-03 Formulations nanoparticulaires stables

Publications (1)

Publication Number Publication Date
NO20076120L true NO20076120L (no) 2007-11-27

Family

ID=38309654

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076120A NO20076120L (no) 2005-05-05 2007-11-27 Stabile nanopartikkelformuleringer

Country Status (15)

Country Link
US (1) US20080038359A1 (fr)
EP (1) EP1895982A2 (fr)
JP (1) JP5483874B2 (fr)
KR (2) KR20080015077A (fr)
CN (1) CN101252914B (fr)
AU (2) AU2006336414B2 (fr)
BR (1) BRPI0611433A2 (fr)
CA (1) CA2606861C (fr)
IL (1) IL187128A0 (fr)
MA (1) MA29492B1 (fr)
NO (1) NO20076120L (fr)
NZ (1) NZ562559A (fr)
RU (1) RU2409352C2 (fr)
WO (1) WO2007086911A2 (fr)
ZA (1) ZA200708633B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7923478B2 (en) * 2006-12-28 2011-04-12 Bridgestone Corporation Nanoporous polymeric material and preparation method
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2013041944A1 (fr) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Procédé pour la préparation de candésartan cilexétil micronisé
CN104174468B (zh) * 2014-08-27 2016-06-15 上海延安药业有限公司 粘稠性药物锆珠研磨方法
ES2953512T3 (es) * 2016-04-15 2023-11-14 Epizyme Inc Compuestos de arilo o heteroarilo sustituidos con amina como inhibidores de EHMT1 y EHMT2

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263310A (en) * 1974-03-02 1981-04-21 Boehringer Ingelheim Gmbh 8-Bromo-6-(o-chloro-phenyl)-4H-S-triazolo-[3,4,-c]-thieno-[2,3-e]-1,4-diazepines and salts thereof
US4322440A (en) * 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
CA2019719A1 (fr) * 1990-06-25 1991-12-25 William J. Thompson Bain de bouche
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
JPH05305226A (ja) * 1992-04-28 1993-11-19 Takeda Chem Ind Ltd 粒子及びその製造法
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
ATE233549T1 (de) * 1998-06-19 2003-03-15 Skyepharma Canada Inc Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm
US6200590B1 (en) * 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
WO2001045674A1 (fr) * 1999-12-20 2001-06-28 Cocensys, Inc. Procede de production de particules d'echelle nanometrique par sechage par atomisation en lit fluidise
FR2813306B1 (fr) * 2000-08-23 2005-10-21 Sanofi Synthelabo Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
US7105176B2 (en) * 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
WO2002045692A1 (fr) * 2000-12-07 2002-06-13 Altana Pharma Ag Preparation pharmaceutique sous forme de suspension contenant un ingredient actif labile en milieu acide
MXPA03006958A (es) * 2001-02-05 2003-11-18 Upjohn Co Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
GB0127832D0 (en) * 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
WO2003047497A1 (fr) * 2001-12-06 2003-06-12 Ranbaxy Laboratories Limited Compositions d'isotretinoine nanoparticulaire
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
ATE411010T1 (de) * 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
DE50312980D1 (de) * 2003-05-07 2010-09-23 Kemira Pigments Oy Ftstoffen und aromen
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법

Also Published As

Publication number Publication date
KR20140002810A (ko) 2014-01-08
AU2006336414A1 (en) 2007-08-02
EP1895982A2 (fr) 2008-03-12
HK1120417A1 (en) 2009-04-03
RU2409352C2 (ru) 2011-01-20
ZA200708633B (en) 2009-01-28
CN101252914A (zh) 2008-08-27
JP5483874B2 (ja) 2014-05-07
AU2010241245A1 (en) 2010-11-25
CA2606861A1 (fr) 2007-08-02
US20080038359A1 (en) 2008-02-14
NZ562559A (en) 2011-03-31
CN101252914B (zh) 2013-03-27
MA29492B1 (fr) 2008-05-02
BRPI0611433A2 (pt) 2010-09-08
KR20080015077A (ko) 2008-02-18
IL187128A0 (en) 2008-06-05
WO2007086911A2 (fr) 2007-08-02
RU2007145055A (ru) 2009-06-10
WO2007086911A3 (fr) 2008-04-17
JP2008540439A (ja) 2008-11-20
CA2606861C (fr) 2012-08-07
AU2006336414B2 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
TW200716646A (en) (S)-N-methylnaltrexone
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
WO2009012303A3 (fr) Nanoparticules thérapeutiques stables
NO20085338L (no) Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
NO20090305L (no) Cyklosporin formuleringer
IL183274A0 (en) Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments
NO20075136L (no) Nye liposompreparater
TNSN08284A1 (en) Masking the taste of powders
DK1543063T3 (da) Medikament levering
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
NO20076120L (no) Stabile nanopartikkelformuleringer
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
WO2006002077A3 (fr) Formulations pharmaceutiques stables de composes de benzimidazole
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
UA97629C2 (ru) Фармацевтическая композиция, имеющая противоопухолевую активность, и способы
DE602004022515D1 (de) Fenofibrate tablett und verfahren zur herstellung
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
NO20075508L (no) Stannsoporfinpreparater og administrering
ATE481392T1 (de) Benzimidazolderivate zur behandlung entzündlicher erkrankungen
MY148088A (en) Stable nanoparticle formulations
DK1962822T3 (da) Terapi af maligne neoplasier
EA200701903A1 (ru) Способ получения быстрорастворимого порошка имидаприла
NO20065853L (no) Hydrogelinterferonformuleringer
CY1114525T1 (el) (s)-n-methylnaltrexone,(μεθυλναλτρεξονη), διαδικασιες για την συνθεση της και η φαρμακευτικη της χρηση

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application